Evaxion Biotech AS (EVAX) - Total Assets
Based on the latest financial reports, Evaxion Biotech AS (EVAX) holds total assets worth $29.74 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See EVAX book value for net asset value and shareholders' equity analysis.
Evaxion Biotech AS - Total Assets Trend (2017–2024)
This chart illustrates how Evaxion Biotech AS's total assets have evolved over time, based on quarterly financial data.
Evaxion Biotech AS - Asset Composition Analysis
Current Asset Composition (December 2024)
Evaxion Biotech AS's total assets of $29.74 Million consist of 70.2% current assets and 29.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 40.5% |
| Accounts Receivable | $1.86 Million | 14.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Evaxion Biotech AS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Evaxion Biotech AS (EVAX) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Evaxion Biotech AS's current assets represent 70.2% of total assets in 2024, a decrease from 92.9% in 2017.
- Cash Position: Cash and equivalents constituted 40.5% of total assets in 2024, up from 15.9% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 14.9% of total assets.
Evaxion Biotech AS Competitors by Total Assets
Key competitors of Evaxion Biotech AS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Evaxion Biotech AS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.42 | 2.80 | 6.36 |
| Quick Ratio | 3.42 | 2.80 | 6.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $12.86 Million | $6.88 Million | $9.24 Million |
Evaxion Biotech AS - Advanced Valuation Insights
This section examines the relationship between Evaxion Biotech AS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.81 |
| Latest Market Cap to Assets Ratio | 2.24 |
| Asset Growth Rate (YoY) | -3.1% |
| Total Assets | $12.48 Million |
| Market Capitalization | $28.02 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Evaxion Biotech AS's assets at a significant premium (2.24x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Evaxion Biotech AS's assets decreased by 3.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Evaxion Biotech AS (2017–2024)
The table below shows the annual total assets of Evaxion Biotech AS from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $12.48 Million | -3.13% |
| 2023-12-31 | $12.89 Million | -41.48% |
| 2022-12-31 | $22.02 Million | -45.16% |
| 2021-12-31 | $40.16 Million | +235.67% |
| 2020-12-31 | $11.96 Million | +7.95% |
| 2019-12-31 | $11.08 Million | +30.20% |
| 2018-12-31 | $8.51 Million | +188.67% |
| 2017-12-31 | $2.95 Million | -- |
About Evaxion Biotech AS
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected mel… Read more